GW Pharmaceuticals PLC (NASDAQ:GWPH) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Monday.

A number of other analysts have also commented on the company. Maxim Group set a $135.00 target price on GW Pharmaceuticals PLC and gave the company a “buy” rating in a research report on Thursday, June 8th. Zacks Investment Research raised GW Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $119.00 price target on the stock in a research note on Monday, July 17th. Cantor Fitzgerald set a $208.00 price target on GW Pharmaceuticals PLC and gave the stock a “buy” rating in a report on Tuesday, August 8th. BidaskClub upgraded GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a report on Wednesday, June 21st. Finally, Leerink Swann reduced their price objective on GW Pharmaceuticals PLC from $160.00 to $153.00 and set an “outperform” rating for the company in a research note on Monday. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. GW Pharmaceuticals PLC has an average rating of “Buy” and a consensus price target of $149.83.

GW Pharmaceuticals PLC (NASDAQ:GWPH) traded down 2.94% on Monday, hitting $98.51. The company had a trading volume of 1,297,826 shares. GW Pharmaceuticals PLC has a one year low of $92.65 and a one year high of $137.88. The stock’s 50-day moving average price is $105.31 and its 200 day moving average price is $108.39. The company’s market capitalization is $2.49 billion.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last announced its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, missing the consensus estimate of ($1.73) by ($0.34). The company had revenue of $3.14 million for the quarter, compared to analyst estimates of $2.10 million. GW Pharmaceuticals PLC had a negative net margin of 1,384.41% and a negative return on equity of 28.80%. During the same quarter in the prior year, the company posted ($0.05) EPS. On average, analysts expect that GW Pharmaceuticals PLC will post ($5.94) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/10/02/gw-pharmaceuticals-plc-gwph-stock-rating-lowered-by-valuengine.html.

Institutional investors have recently modified their holdings of the company. Janus Henderson Group PLC bought a new position in shares of GW Pharmaceuticals PLC in the second quarter valued at approximately $70,128,000. Redmile Group LLC boosted its position in shares of GW Pharmaceuticals PLC by 33.8% during the second quarter. Redmile Group LLC now owns 444,936 shares of the biopharmaceutical company’s stock valued at $44,605,000 after buying an additional 112,392 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of GW Pharmaceuticals PLC during the first quarter valued at approximately $10,909,000. Nomura Holdings Inc. purchased a new position in shares of GW Pharmaceuticals PLC during the first quarter valued at approximately $9,389,000. Finally, Employees Retirement System of Texas purchased a new position in shares of GW Pharmaceuticals PLC during the second quarter valued at approximately $5,313,000. 75.06% of the stock is owned by hedge funds and other institutional investors.

GW Pharmaceuticals PLC Company Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Analyst Recommendations for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Receive News & Stock Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.